ASIMOV
Intelligent design, for cells that follow instructions.
Pictured: Asimov's RNA Edge System - the closest thing biology has to a "build" button. Yes, the company is named after that Asimov.
Intelligent design, for cells that follow instructions.
Pictured: Asimov's RNA Edge System - the closest thing biology has to a "build" button. Yes, the company is named after that Asimov.
Who they are now
In a lab off Brookline Avenue, a scientist types a specification into a browser tab, clicks, and waits. Not for code to build, but for a strand of DNA to be designed - vector layout, promoters, coding sequences, all optimized to run inside a living cell. This is Asimov on an ordinary Tuesday. The company treats biology the way a chip designer treats silicon: as something you can draw, simulate, and debug before you ever touch a bench.
Asimov sells the unglamorous middle of modern medicine. Not the drug, not the patient - the toolchain that gets the drug made. Its platform, Kernel, comes preloaded with more than 600,000 searchable sequences and a thousand-plus validated genetic parts. Its "Edge" systems handle the messy production reality of antibodies, viral vectors, and RNA. The pitch is almost suspiciously simple: make programming a cell feel like programming a machine.
The problem they saw
Here is the uncomfortable truth the industry rarely advertises: we have learned to design astonishing therapies - cell therapies, gene therapies, RNA medicines - and we still manufacture many of them with methods closer to artisanal craft than to engineering. Each new modality arrives with its own bespoke production headaches. Cost, quality, and scale fight each other. A brilliant molecule can die not in the clinic, but in the plant.
Genetic engineering, for most of its history, has been an art. Talented people, hard-won intuition, lots of trial and a great deal of error. Asimov's founders found that charming and also, frankly, unacceptable. Other fields - semiconductors, aerospace - escaped the craft era by adopting abstraction, standardization, and modeling. Biology, they argued, deserves the same upgrade.
Asimov's framing: every mature engineering discipline eventually gets a CAD tool. Biology was overdue for its turn - and somewhat indignant about being skipped.
The founders' bet
The story starts not with a pitch deck but with a collaboration. Christopher Voigt at MIT and Douglas Densmore at Boston University spent years building the foundations of genetic logic circuit design - the idea that you could wire instructions into cells the way you wire logic into a circuit. Alec Nielsen joined Voigt's lab as a PhD student and caught the same fever. Raja Srinivas rounded out the founding team.
In 2016, the group, with collaborators at NIST, released Cello: a platform that literally compiles a high-level logic specification into working DNA. It was a proof that biology could be programmed, not just coaxed. A year later, in 2017, they spun that conviction into a company and named it after Isaac Asimov - the writer who imagined laws governing intelligent systems. The wink is intentional.
The bet was that the bottleneck in biotech was no longer ideas, but tooling. If you gave drug makers a real design environment - searchable parts, predictive models, version control for DNA - you would not just speed up science. You would change who gets to do it.
The receipts
With collaborators at NIST, the founders publish a platform for automated genetic circuit design - the technical seed of everything that follows.
The team spins out of MIT and Boston University labs, with early backing from Andreessen Horowitz and DARPA.
Led by Horizons Ventures. The MIT-Broad Foundry joins to deepen synthetic biology R&D.
Led by CPP Investments, with Fidelity, Casdin, Pillar, KDT, a16z and Horizons. Total raised crosses $200M.
Partners with iGEM to accelerate mammalian synthetic biology and teams with AGC Biologics on viral vector manufacturing.
The product
At the center sits Kernel - a cloud-based CAD platform for biology. Scientists design genetic systems, simulate them across different cell types, debug them, and store them with version history. Asimov likes to call it "GitHub for DNA," which is either marketing or a genuinely useful mental model, depending on how cynical you are feeling. A Genetic Compiler bridges modeling and design, guiding vector layouts and coding-sequence optimization to fit each molecule and host.
Then come the Edge systems - integrated design-and-manufacturing kits for the modalities that keep drug makers awake at night.
Design, simulate, and debug genetic systems in the cloud. 600,000+ searchable sequences out of the box.
Protein and biologics expression in CHO cells, the workhorse of the industry.
Lentiviral and adeno-associated virus vector production for cell and gene therapy.
Design and production system for RNA-based therapeutics.
The proof
Conviction is cheap; capital is not. Asimov has raised over $200 million. The headline is the January 2023 Series B: $175 million led by Canada Pension Plan Investment Board, with Fidelity, Casdin Capital, Pillar, KDT, Andreessen Horowitz, and Horizons Ventures along for the ride. That follows a $25 million Series A led by Horizons. The money is earmarked for scaling tools and services across biologics, cell and gene therapy, and RNA.
Capital raised by round (USD millions)
Series B (Jan 2023) led by CPP Investments. Bars scaled to the $175M round; total includes earlier capital.
Asimov reports working with 25-plus organizations, including major pharmaceutical and biotech firms. It teamed with AGC Biologics on a simpler, more cost-effective approach to viral vector production, and partnered with iGEM - the global student synthetic biology competition - to push mammalian synthetic biology into the next generation of researchers.
"There is an accelerating demand for new tools and services to develop and manufacture complex novel drug products." - Leon Pedersen, CPP Investments.
The mission
Stripped of the jargon, Asimov's mission is a verb: design. The company wants to radically advance humanity's ability to design living systems, and it believes the way to get there is to give biology the same scaffolding that matured every other field - abstraction, standardization, characterization, and modeling. Less intuition. More instrumentation.
Internally, the culture is built around a slightly unusual word - "recombination," the deliberate mixing of disciplines and perspectives. Add mission-first decision-making, a bias toward continuous learning, and a stated sense of urgency, and you get a company that behaves like it genuinely believes the clock is running. Which, given who is waiting on better medicines, it is.
Why it matters tomorrow
Return to the scientist off Brookline Avenue, typing a specification and clicking build. A decade ago, that idea was a research stunt. Today it is a product with paying customers and a quarter-billion dollars of conviction behind it. The strand of DNA that comes back is not magic. It is engineering - searchable, simulated, versioned, and increasingly boring in the best possible way.
That is the whole point. Asimov is trying to make the hardest part of new medicine feel routine. If they are right, the next breakthrough therapy will not stall in a factory. It will compile, run, and scale. And the people designing it may never have to guess.
The cells, for their part, are finally getting instructions they can follow.
Go deeper